News Related to UPLIZNA

Related coverage linked through entity extraction aliases.

Amgen Stock Rises on Pipeline Expansion and Strong Q4 Results

Mar 03, 2026

Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.

Amgen's Uplizna Wins FDA and European Approval for Generalized Myasthenia Gravis

Dec 11, 2025

Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.